Difficulty: Medium
Average Score: 84%
Practice
The drug which abolishes the therapeutic effect of levodopa in Parkinsonism, but not that of levodopa-carbidopa combination is
Correct answer
B
Rationale
In the context of CNS drugs, especially in the treatment of Parkinsonism, understanding drug interactions is crucial. The correct answer to this question is B) Pyridoxine. Pyridoxine, also known as vitamin B6, abolishes the therapeutic effect of levodopa alone but not the combination of levodopa-carbidopa.
Levodopa is the precursor to dopamine and is a key medication in managing Parkinsonism. When levodopa is administered alone, a portion of it gets converted to dopamine peripherally, reducing the amount that reaches the brain. Pyridoxine enhances this peripheral conversion, thereby diminishing the therapeutic effect. On the other hand, the combination of levodopa-carbidopa includes carbidopa, which inhibits the peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain and be converted to dopamine centrally.
Now, let's discuss why the other options are incorrect:
A) Metoclopramide: While metoclopramide can increase the absorption of levodopa, it does not abolish its therapeutic effect in the same way as pyridoxine.
C) Chlorpromazine: This drug is not known to specifically interfere with the therapeutic effect of levodopa in Parkinsonism.
D) Isoniazid: Isoniazid is used to treat tuberculosis and does not have a direct effect on levodopa therapy in Parkinsonism.
Understanding these drug interactions is vital for healthcare professionals managing patients with Parkinsonism. It highlights the importance of considering not only the primary medication but also potential interactions that may impact treatment efficacy. This knowledge can help in optimizing treatment outcomes and avoiding unintended consequences in patient care.
Levodopa is the precursor to dopamine and is a key medication in managing Parkinsonism. When levodopa is administered alone, a portion of it gets converted to dopamine peripherally, reducing the amount that reaches the brain. Pyridoxine enhances this peripheral conversion, thereby diminishing the therapeutic effect. On the other hand, the combination of levodopa-carbidopa includes carbidopa, which inhibits the peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain and be converted to dopamine centrally.
Now, let's discuss why the other options are incorrect:
A) Metoclopramide: While metoclopramide can increase the absorption of levodopa, it does not abolish its therapeutic effect in the same way as pyridoxine.
C) Chlorpromazine: This drug is not known to specifically interfere with the therapeutic effect of levodopa in Parkinsonism.
D) Isoniazid: Isoniazid is used to treat tuberculosis and does not have a direct effect on levodopa therapy in Parkinsonism.
Understanding these drug interactions is vital for healthcare professionals managing patients with Parkinsonism. It highlights the importance of considering not only the primary medication but also potential interactions that may impact treatment efficacy. This knowledge can help in optimizing treatment outcomes and avoiding unintended consequences in patient care.